AN6 Stock Overview
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
AnaptysBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.80 |
| 52 Week High | US$36.40 |
| 52 Week Low | US$12.30 |
| Beta | -0.24 |
| 11 Month Change | -35.00% |
| 3 Month Change | -37.72% |
| 1 Year Change | 60.00% |
| 33 Year Change | -23.53% |
| 5 Year Change | 71.19% |
| Change since IPO | -61.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| AN6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.2% | 0.8% | -1.3% |
| 1Y | 60.0% | -17.5% | 7.4% |
Return vs Industry: AN6 exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: AN6 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| AN6 volatility | |
|---|---|
| AN6 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AN6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AN6's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 117 | Dan Faga | www.anaptysbio.com |
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.
AnaptysBio, Inc. Fundamentals Summary
| AN6 fundamental statistics | |
|---|---|
| Market cap | €618.60m |
| Earnings (TTM) | -€159.08m |
| Revenue (TTM) | €54.90m |
11.9x
P/S Ratio-4.1x
P/E RatioIs AN6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AN6 income statement (TTM) | |
|---|---|
| Revenue | US$57.17m |
| Cost of Revenue | US$154.78m |
| Gross Profit | -US$97.60m |
| Other Expenses | US$68.05m |
| Earnings | -US$165.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.44 |
| Gross Margin | -170.72% |
| Net Profit Margin | -289.75% |
| Debt/Equity Ratio | 415.5% |
How did AN6 perform over the long term?
See historical performance and comparison